GBM Clinical Trial
Official title:
A Prospective Phase I/II Clinical Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM.
This phase I/II clinical trial is intended to investigate the efficacy and safety of SVZ irradiation with postoperative radiotherapy in patients with GBM.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 30, 2025 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Patients voluntarily join this study, have the ability to understand and are willing to sign the informed consent form. 2. Aged between 18-70 years old (inclusive). 3. Newly diagnosed glioblastoma confirmed by pathology. 4. The patient must have undergone maximum surgical resection and start radiotherapy within 12 weeks after surgery. 5. MRI shows that the patient's SVZ area is involved or the distance between the tumor and the SVZ area is less than or equal to 1cm. 6. No previous brain irradiation. 7. Women of childbearing age have a negative urine test or serum pregnancy test and are contraceptive during the treatment period. 8. The ECOG performance status assessed within 7 days before the study intervention is 0-1 points. 9. Have sufficient organ function, and the subject needs to meet the following laboratory indicators: 1. Absolute neutrophil count (ANC) =1.5x109/L without using granulocyte colony-stimulating factor in the past 14 days. 2. Without blood transfusion in the past 14 days, platelets are =80×109/L. 3. Without blood transfusion or erythropoietin use in the past 14 days, hemoglobin =9g/dL (90g/L) or =5.6mmol/L. 4. Total bilirubin =1.5×upper limit of normal (ULN); or total bilirubin >1.5×ULN but direct bilirubin =SULN. 5. aspartate aminotransferase (AST), alanine aminotransferase (ALT) =2.5×ULN, or subjects with liver metastasis =5× ULN. 6. Serum creatinine = 1.5 × ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) = 60 ml/min. 7. Good coagulation function: International normalized ratio (INR) or prothrombin time (PT) = 1.5 times ULN; or the subject is receiving anticoagulant therapy but the prothrombin time (PT) or partial thromboplastin time (PTT) is within the therapeutic range for the anticoagulant's intended use; • Activated partial thromboplastin time (aPTT) ) or partial thromboplastin time (PTT) =1.5 times ULN; or the subject is receiving anticoagulant therapy, but the prothrombin time (PT) or activated partial thromboplastin time (PTT) is below the expected use of the anticoagulant Within the therapeutic range; 8. Normal thyroid function, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH is outside the normal range, subjects can also be enrolled if total T3 (or FT3) and FT4 are within the normal range. 9. myocardial enzyme spectrum is within the normal range (such as a simple experiment that is not clinically significant in the comprehensive judgment of the researcher). Ventricular abnormalities are also allowed to be included); simple laboratory abnormalities are also allowed to be included). Exclusion Criteria: 1. Have a personal history of malignant tumors within two years. 2. Use anti-vascular drugs such as bevacizumab before progression. 3. Women who are pregnant or breastfeeding, and women of childbearing age who are unwilling or unable to accept birth control methods during the entire study period and up to 12 weeks after the study. 4. Physical examination or clinical experimental findings that the researcher believes may interfere with the results or increase the patient's risk of treatment complications. 5. Unstable systemic accompanying diseases (active infection stage, moderate to severe chronic obstructive pulmonary disease, poorly controlled high blood pressure) Blood pressure disease, unstable angina, congestive heart failure, myocardial infarction within 6 months, severe mental disorder requiring drug control, liver, kidney or other metabolic diseases, neuropsychiatric changes such as Alzheimer's disease). 6. There may be other medical history or disease evidence that may interfere with the trial results, prevent the subject from fully participating in the study, abnormal treatment or laboratory test values, or other conditions that the researcher believes are not suitable for enrollment. The researcher believes that there are other potential risks and are not suitable for participation. this research. allowed to join the group). |
Country | Name | City | State |
---|---|---|---|
China | Lining Guo | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Cancer Institute & Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PFS | Progression-free survival (PFS), defined as the time from treatment to progression or death, whichever occurs first; | 12 monnths | |
Secondary | OS | Overall survival (OS), defined as the time from treatment to death. | 12 monnths | |
Secondary | Safety evaluation | Adverse events were assessed according to NCI CTCAE (version 5.0) | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06147505 -
Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
Completed |
NCT01478178 -
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
|
Phase 1/Phase 2 | |
Terminated |
NCT03119064 -
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05686798 -
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
|
Phase 1 | |
Recruiting |
NCT03758014 -
Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01205334 -
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00114309 -
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
|
Phase 2 | |
Not yet recruiting |
NCT03746288 -
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
|
Phase 2 | |
Terminated |
NCT04681677 -
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
|
Phase 2 | |
Completed |
NCT01856933 -
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
|
Phase 2 | |
Terminated |
NCT04763031 -
Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT
|
N/A | |
Completed |
NCT00107003 -
GW572016 to Treat Recurrent Malignant Brain Tumors
|
Phase 2 | |
Completed |
NCT03426891 -
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
|
Phase 1 | |
Recruiting |
NCT04115761 -
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
|
Phase 2 | |
Recruiting |
NCT05954858 -
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
|
N/A | |
Not yet recruiting |
NCT06388733 -
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
|
Phase 3 | |
Recruiting |
NCT02861898 -
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 |